Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 1K citations · Full text

Pharmacy, Oncology, Outcomes Research +13

Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions

Giuliano Ciarimboli, Dirk Deuster, Arne Knief et al. · American Journal Of Pathology · 2010 · 441 citations · Full text

Medicine, Oncology, Pharmacology +15

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Kelly K. Filipski, Ron H.J. Mathijssen, Torben Stamm Mikkelsen et al. · Clinical Pharmacology & Therapeutics · 2009 · 401 citations · Full text

Medicine, Oncology, Pharmacology +17

Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose

Yuelin Li, Richard B. Womer, Jeffrey H. Silber · European Journal of Cancer · 2003 · 356 citations

Medicine, Otolaryngology, Pharmacology +14

Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer

Carsten Bokemeyer, C. Berger, J T Hartmann et al. · British Journal of Cancer · 1998 · 341 citations · Full text

Medicine, Oncology, Toxicology +15